Related Experiment Video
Updated: Jan 10, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Reprogramming the Immune Suppressive Tumor Microenvironment in Glioma Enhances the Efficacy of Immune-Mediated Gene
Abstract:
Gliomas account for ~80% of primary malignant brain tumors. Many CNS WHO grade 2-3 and some grade 4 gliomas harbor mutant isocitrate dehydrogenase 1 (mIDH1), which causes a gain of function mutation (IDH1 R132H) leading to the production of 2-hydroxyglutarate (2HG). Mutant IDH1-induced 2HG, through epigenetic reprogramming elicits an immune-permissive tumor microenvironment (TME). An immunosuppressive mechanism in the glioma TME involves adenosine production via the ectoenzyme CD73. This study investigates mIDH1's influence on CD73 expression and adenosine levels. We demonstrate that mIDH1 glioma cells exhibit reduced CD73 expression, driven by DNA hypermethylation, leading to reduced adenosine levels. Since wtIDH1 gliomas have high CD73 expression, we evaluated CD73 blockade as an immunotherapy target. We show that CD73 inhibition used as monotherapy, did not improve survival in wtIDH1 glioma-bearing mice. However, when combined with immune-stimulatory Ad-TK (adenoviral vectors encoding herpes simplex virus thymidine kinase) and Ad-Flt3L (adenoviral vectors encoding FMS-like tyrosine kinase 3 ligand) gene therapy, CD73 blockade significantly enhanced therapeutic efficacy and increased anti-glioma effector T cell activity. These findings reveal that CD73 inhibition used in combination with immune stimulatory Ad-TK/Ad-Flt3L gene therapy may be an effective treatment for wtIDH1 gliomas, which could be readily translated to the clinical arena.
Insights
Mutant IDH1 (mIDH1) gliomas show lower CD73 expression, reducing adenosine. CD73 blockade combined with gene therapy significantly improved survival in wild-type IDH1 (wtIDH1) gliomas by boosting anti-tumor T cell activity.
Area of Science:
- Neuro-oncology
- Cancer Immunology
- Molecular Biology
Background:
- Gliomas are primary malignant brain tumors, with many harboring mutations in isocitrate dehydrogenase 1 (IDH1).
- Mutant IDH1 (mIDH1) promotes an immune-permissive tumor microenvironment (TME), but adenosine produced by CD73 contributes to immunosuppression.
- Wild-type IDH1 (wtIDH1) gliomas exhibit high CD73 expression, presenting a potential therapeutic target.
Purpose of the Study:
- To investigate the impact of mIDH1 on CD73 expression and adenosine levels in gliomas.
- To evaluate CD73 blockade as a monotherapy and in combination with gene therapy for glioma treatment.
Main Methods:
- Analysis of CD73 expression in mIDH1 and wtIDH1 glioma cells.
- Assessment of adenosine levels in relation to CD73 expression.
- In vivo studies using glioma-bearing mice to test CD73 inhibition alone and combined with Ad-TK and Ad-Flt3L gene therapy.
Main Results:
- mIDH1 glioma cells displayed reduced CD73 expression due to DNA hypermethylation, leading to lower adenosine levels.
- CD73 inhibition as monotherapy did not improve survival in wtIDH1 glioma-bearing mice.
- Combination therapy (CD73 blockade with Ad-TK/Ad-Flt3L) significantly enhanced therapeutic efficacy and increased anti-glioma T cell activity in wtIDH1 gliomas.
Conclusions:
- CD73 plays a role in regulating adenosine levels in gliomas, influenced by IDH1 mutation status.
- CD73 inhibition alone is insufficient for treating wtIDH1 gliomas.
- Combination therapy involving CD73 blockade and immune-stimulatory gene therapy offers a promising, clinically translatable approach for wtIDH1 gliomas.
More Related Videos
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment